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Objectives. We sought to determine whether the beneficial
effects of amlodipine in heart failure may be mediated by a
reduction in tumor necrosis factor-alpha (TNF-alpha) and
interleukin-6 (IL-6) levels. We postulated that TNF-alpha and
IL-6 levels may also have predictive value in patients with
congestive heart failure (CHF).
Background. The molecular mechanism for progression of CHF
may involve cytokine overexpression. The effect of amlodipine on
cytokine levels in patients with CHF is unknown.
Methods. In the Prospective Randomized Amlodipine Survival
Evaluation (PRAISE) trial, we used enzyme-linked immunosor-
bent assay to measure plasma levels of TNF-alpha in 92 patients
and IL-6 in 62 patients in New York Heart Association functional
classes III and IV randomized to receive amlodipine (10 mg/day)
or placebo. Blood samples were obtained for cytokine measure-
ment at baseline and at 8 and 26 weeks after enrollment.
Results. The baseline amlodipine and placebo groups did not
differ in demographics and cytokine levels. Mean (6SD) plasma
levels of TNF-alpha were 5.69 6 0.32 pg/ml, and those of IL-6 were
9.23 6 1.26 pg/ml at baseline. These levels were elevated 6 and 10
times, respectively, compared with those of normal subjects (p <
0.001). Levels of TNF-alpha did not change significantly over the
26-week period (p 5 0.69). However, IL-6 levels were significantly
lower at 26 weeks in patients treated with amlodipine versus
placebo (p 5 0.007 by the Wilcoxon signed-rank test). An adverse
event—CHF or death—occurred more commonly in patients with
higher IL-6 levels.
Conclusions. Amlodipine lowers plasma IL-6 levels in patients
with CHF. The beneficial effect of amlodipine in CHF may be due
to a reduction of cytokines such as IL-6.
(J Am Coll Cardiol 1997;30:35–41)
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Congestive heart failure (CHF), a major complication of
ischemic heart disease, accounts for a sizable fraction of
cardiovascular morbidity and mortality in the industrialized
world. Over 3 million Americans have CHF, and it is expected
that this number will rise as the U.S. population continues to
age (1,2). When treated with digitalis and diuretic agents
alone, the 1-year mortality rate of patients with severe CHF
(New York Heart Association functional class IV) approaches
50% to 60% (3). In an effort to reduce this dismal statistic, over
the past 5 to 7 years there has been a culmination of several
major multicenter trials of agents that prolong survival.
Angiotensin-converting enzyme (ACE) inhibitors and the
combination of hydralazine and isosorbide dinitrate have been
found to improve 1-year survival by 30% to 40% (3–6).
However, the mechanism of these salutary effects remains
conjectural because vasodilation and afterload reduction may
or may not account for the improved survival.
As Packer (7) and Elkayam et al. (8) recently noted, some
vasodilators (i.e., nifedipine, verapamil, diltiazem) worsen
survival despite equivalent hemodynamic changes. Conse-
quently, other actions of ACE inhibitors and/or the hydralazine/
nitrate combination may confer survival benefit by reducing
heart failure progression or lessening sudden death, or both.
One possibility is that these agents alter neurohormonal
factors that are elevated in severe CHF. The circulatory
compromise attending CHF stimulates the renin-angiotensin
system, which produces vasoconstriction, sodium retention and
elevation of plasma norepinephrine levels. Angiotensin II
levels, plasma renin activity, atrial natriuretic factor, arginine
vasopressin and endothelin-1 are increased in severe CHF and
perhaps other factors as yet unknown (9–11).
A cytokine with potential prognostic importance is tumor
necrosis factor-alpha (TNF-alpha), which is elevated in severe
heart failure (12). This cytokine is synthesized by activated
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macrophages, endothelial cells and the myocardium (13).
Support for TNF-alpha as a pathologic entity in CHF comes
from studies showing that TNF-alpha elevation is associated
with cachexia (14) and marked elevation of the renin-
angiotensin system (13). In addition, TNF-alpha has negative
inotropic action (15) and may induce apoptosis in myocardial
cells (16,17). Furthermore, TNF-alpha can impair synthesis
and accelerate catabolism of protein in skeletal muscle (18),
which may explain the decreased exercise tolerance experi-
enced by patients with severe CHF. Furthermore, TNF-alpha
elevation may not be an epiphenomenon, as several studies
have shown that improvement in CHF status is accompanied
by a decrease in circulating TNF-alpha (19–21).
Another proinflammatory cytokine that may have patho-
logic significance in CHF is interleukin-6 (IL-6). Like TNF-
alpha, IL-6 is expressed by a variety of normal and transformed
cells, including activated macrophages and endothelial cells.
The production of IL-6 is upregulated by numerous signals,
including mitogenic or antigenic stimulation and, interestingly,
TNF-alpha. Recently, IL-6 was found to be elevated in patients
with unstable angina, and markedly elevated levels predicted a
poor clinical outcome (22). Also, elevated levels of IL-6 and
TNF-alpha occurring in the early period after heart transplan-
tation correspond to impaired hemodynamic status indepen-
dent of cellular rejection (23).
In this study we sought to determine if amlodipine’s bene-
ficial effects in heart failure may be mediated by a reduction in
TNF-alpha and IL-6 levels. We postulated that TNF-alpha and
IL-6 levels may also have prognostic value in CHF. If changes
in these markers are correlated with survival, then TNF-alpha
and IL-6 may identify those patients with CHF who may
respond better to therapy.
Methods
Patients. A subset of 92 patients participating in the Pro-
spective Randomized Amlodipine Survival Evaluation
(PRAISE) trial were enrolled in this substudy. Six healthy
control subjects without a history of heart disease were also
enrolled to validate the cytokine assays.
Inclusion criteria. The inclusion criteria for the PRAISE
trial included patients in functional class III and IV heart
failure with a left ventricular ejection fraction ,30% for the 3
months before enrollment. All patients were treated with ACE
inhibitors, digoxin and diuretic agents for at least 2 months
before enrollment. Patients with properly functioning pros-
thetic heart valves were included in the study.
Exclusion criteria. The exclusion criteria for the PRAISE
trial have been published elsewhere (24).
Study design. After written informed consent was ob-
tained, patients were randomized to either placebo or amlo-
dipine, and blood was obtained for cytokine measurement at
baseline and at 8 and 26 weeks after enrollment. An intrave-
nous catheter was inserted at least 30 min before drawing
blood. The blood samples were obtained after the patient
remained in the supine position for at least 30 min.
Measurement of TNF-alpha and IL-6. Blood samples were
collected in test tubes containing EDTA and plasma separated
with centrifugation. The plasma was then placed in test tubes
and frozen at 280°C. Plasma immunoreactive TNF-alpha and
IL-6 levels were measured using a commercially available,
(Quantikine HS, R&D Systems) solid-phase, high sensitivity
enzyme-linked immunosorbent assay (ELISA) according to
the manufacturer’s recommendation.
Statistical analysis. Because IL-6 values were not normally
distributed, a log transformation was used for parametric
analyses. Two-way repeated measures analysis of variance
(ANOVA), using all subjects who completed the study, was
used to test the significance (defined as p , 0.05) of changes in
variables over time during treatment for CHF and for treat-
ment effects. For simple data pairs, the Student t test for paired
or nonpaired data was used to determine the statistical signif-
icance between mean values. The relations between TNF-
alpha and IL-6 levels and survival in all subjects with baseline
data were examined using the Cox proportional hazards re-
gression model. The effects of treatment on survival were
assessed with a Kaplan-Meier survival analysis using the log-
rank test.
Results
Study patients. A total of 92 patients from the PRAISE
trial were enrolled in this study—45 were randomized to
amlodipine and 47 to placebo (Table 1). There were 62
patients with ischemic cardiomyopathy and 30 patients with
nonischemic cardiomyopathy. The mean (6SE) age for these
92 patients was 61.3 6 10.5 years. Compared with the PRAISE
study demographics (24), our subjects were slightly younger
(PRAISE: 64.7 years; present study: 61.3 years, respectively,
p , 0.01) and less likely to be in functional class IV (PRAISE:
931 in functional class III, 222 in functional class IV; present
study: 83 in functional class III, 9 in functional class IV, p 5
0.025). There were no significant differences between the
ischemic and nonischemic groups. Plasma was obtained for
TNF-alpha measurement in all 92 patients at baseline, but
plasma was not available for analysis in 26 patients at follow-up
owing to insufficient quantity of plasma, dropout or death. Of
the 66 patients with follow-up TNF-alpha measurements, 29
were randomized to amlodipine and 37 to placebo. There were
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
CHF 5 congestive heart failure
ELISA 5 enzyme-linked immunosorbent assay
IL-6 5 interleukin-6
IL-6R 5 interleukin-6 receptor
PRAISE 5 Prospective Randomized Amlodipine Survival Evaluation
trial
TNF-alpha 5 tumor necrosis factor-alpha
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45 patients with ischemic cardiomyopathy (19 amlodipine, 26
placebo) and 21 patients with nonischemic cardiomyopathy (10
amlodipine, 11 placebo).
Plasma was obtained for IL-6 measurement in 66 patients at
baseline, but plasma was not available for analysis in 23
patients at follow-up owing to insufficient quantity of plasma,
dropout or death. Of the 39 patients with follow-up IL-6
measurements, 19 were randomized to amlodipine and 20 to
placebo. There were 40 patients with ischemic cardiomyopathy
(12 receiving amlodipine therapy, 15 placebo) and 22 patients
with nonischemic cardiomyopathy (7 receiving amlodipine, 5
placebo). Although previous studies were done to validate the
assays, six healthy control subjects without heart disease were
tested for TNF-alpha and IL-6 levels to validate the assays in
our laboratory. Our results for TNF-alpha and IL-6 levels in
healthy control subjects compared closely with the results for
healthy individuals reported by R&D Systems, as detailed in
the next sections.
Results for TNF-alpha. The baseline mean (6SE) TNF-
alpha level for the 92 PRAISE study patients was 5.69 6 0.32
pg/ml and for the six healthy control subjects it was 0.89 6 0.12
pg/ml, which was significantly different (p , 0.001) (Fig. 1).
The mean TNF-alpha levels for our healthy control patients
compares closely with those levels for 75 healthy subjects
reported by R&D Systems (mean 1.3 pg/ml). The 47 patients
randomized to placebo had a baseline mean TNF-alpha level
of 5.53 6 0.23 pg/ml, and the 45 randomized to amlodipine had
a baseline mean TNF-alpha level of 5.86 6 0.38 pg/ml. At
randomization in the PRAISE trial, patients were stratified by
etiology of heart failure—ischemic or nonischemic. The isch-
emic stratum (n 5 62) had a baseline mean TNF-alpha level of
5.63 6 0.41 pg/ml, and the nonischemic stratum (n 5 30) had
a baseline mean TNF-alpha level of 5.83 6 0.54 pg/ml.
The mean (6SE) values for TNF-alpha are shown in Figure
2. The 8-week and 26-week mean TNF-alpha levels for the
ischemic stratum (n 5 45) were 6.42 6 0.80 and 6.0 6 0.64
pg/ml, respectively, and for the nonischemic stratum (n 5 21)
the levels were 5.82 6 0.52 and 5.81 6 0.55 pg/ml, respectively.
Comparison of plasma TNF-alpha levels at baseline and at 8
and 26 weeks after enrollment for patients with complete data
and treated with either amlodipine (n 5 29) or placebo (n 5
37) showed no statistically significant difference using two-way
ANOVA (p 5 0.69).
Results for IL-6. The baseline mean (6SE) IL-6 level for
the 62 PRAISE study patients was 9.23 6 1.26 pg/ml and for
Table 1. Baseline Demographic Characteristics
TNF-Alpha IL-6
Overall
(n 5 92)
Amlodipine
(n 5 45)
Placebo
(n 5 47)
Overall
(n 5 62)
Amlodipine
(n 5 33)
Placebo
(n 5 29)
NYHA class
III 83 42 41 55 30 25
IV 9 3 6 7 3 4
Etiology
Isch 62 31 31 40 22 18
Nonisch 30 14 16 22 11 11
Age (yr)
Mean 61.3 62.3 60.4 62.9 64.2 61.4
6SE 610.5 610.8 610.2 69.3 69.2 69.3
Gender
Male 75 37 38 51 28 23
Female 17 8 9 11 5 6
Weight (kg)
Mean 86.3 88.5 84.3 86.1 91.1 80.3
6SE 622.2 625.0 619.3 622.7 626.8 615.3
Smoker
Present 20 6 14 11 3 8
Non/ex 72 39 33 51 30 21
IL-6 5 interleukin-6; Isch 5 ischemic; Nonisch 5 nonischemic; NYHA
class 5 New York Heart Association functional class; TNF-alpha 5 tumor
necrosis factor-alpha.
Figure 1. Mean (6SE) levels of TNF-
alpha and IL-6 at baseline for patients
with CHF and for healthy control sub-
jects. Cytokine levels were significantly
higher (p , 0.001) in patients with CHF.
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the six healthy control subjects it was 0.55 6 0.12 pg/ml, which
was significantly different (p , 0.001) (Fig. 1). The mean IL-6
levels of our healthy control subjects compares closely with
those levels for 76 healthy subjects reported by R&D Systems
(mean 1.3 pg/ml). The 33 patients randomized to placebo had
a baseline mean IL-6 level of 9.50 6 1.07 pg/ml, and the 29
randomized to amlodipine had a baseline mean IL-6 level of
8.78 6 0.94 pg/ml. The ischemic stratum (n 5 40) had a
baseline mean IL-6 level of 8.82 6 1.42 pg/ml, and the
nonischemic stratum (n 5 22) had a baseline mean IL-6 level
of 9.98 6 2.5 pg/ml.
The mean (6SE) values for IL-6 are shown in Figure 3 for
patients who had all three measurements. The 8-week and
26-week mean IL-6 levels for the ischemic stratum (n 5 27)
were 9.06 6 1.14 and 7.22 6 1.61 pg/ml, respectively, and for
the nonischemic stratum (n 5 12) the levels were 7.38 6 3.49
and 8.07 6 2.82 pg/ml, respectively. Comparison of the log
transformation of plasma IL-6 levels at baseline and at 8 and
26 weeks using repeated measures ANOVA showed a nonsig-
nificant reduction of IL-6 levels at 26 weeks in those patients
treated with amlodipine. The Wilcoxon signed-rank test was
also used within groups to determine if there were significant
changes between baseline and 26-week measurements, be-
cause the data were skewed. We found a significant reduction
in IL-6 levels in patients treated with amlodipine (p 5 0.007)
compared with those receiving placebo (p 5 0.526). The
relatively small number of patients in the ischemic and nonisch-
emic subgroups did not allow for meaningful subgroup analysis
within treatment groups.
Predictive value of cytokines in survival. Analysis of end
points was done using baseline cytokine levels. There was no
difference between the two treatment groups in baseline
Figure 2. Mean (6SE) levels of TNF-
alpha in patients with functional class III
and IV CHF. Comparison of plasma
TNF-alpha levels at baseline and at 8
and 26 weeks after enrollment for pa-
tients treated with either amlodipine
(n 5 29) or placebo (n 5 37) did not
reach statistical significance (p 5 0.69)
using two-way ANOVA.
Figure 3. Mean (6SE) levels of IL-6 in
patients with functional class III and IV
CHF. A comparison of plasma IL-6 lev-
els at baseline and 26 weeks is shown.
The Wilcoxon signed-rank test showed a
significant reduction of IL-6 levels (p 5
0.007) in those patients treated with
amlodipine.
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cytokine levels. Events included hospital admission for CHF
and death. The Student t test and Fisher exact test were used
to determine if there were any statistical differences between
subjects who did and did not have an adverse event. Using all
end points, mean IL-6 levels were higher in those who had an
event (p 5 0.048). Using only death as an end point, a
significant difference in mean values was noted with IL-6 (p 5
0.018). Functional class was also significant (p 5 0.025) with
death as the end point. Patients in functional class IV were
more likely to die earlier than those in class III. There were no
differences in baseline TNF-alpha levels, age or gender using
all end points combined or only death as the end point.
A Kaplan-Meier survival analysis was done to evaluate the
effect of treatment on time to end point, and the Cox regres-
sion model to assess if functional class and IL-6 can predict
time to end point measured in days. Analysis of the treatment
effect included all 92 patients, and there were no significant
differences in survival based on treatment for any end point
(p 5 0.569) or death (p 5 0.369). Therefore, we pooled both
treatment groups to evaluate cytokine and demographic vari-
ables. There were 61 patients with 23 adverse events analyzed.
Statistical analysis revealed an odds ratio (OR) for IL-6 of
1.029 (95% confidence interval [CI] 0.994 to 1.066, p 5 0.067)
and an OR for functional class of 1.331 (95% CI 0.801 to 2.211,
p 5 0.260). There were 61 patients with 18 deaths analyzed.
Neither IL-6 (OR 1.035 [95% CI 0.992 to 1.075], p 5 0.067)
nor functional (OR 1.557 [95% CI 0.916 to 2.646] p 5 0.095)
was significant alone at the p , 0.05 level. However, when
these two variables were combined the overall significance
level was p 5 0.04. A larger sample size would allow a
definitive assessment of whether IL-6 is a statistically signifi-
cant predictor of survival.
Discussion
The idea that improved hemodynamic performance result-
ing from pharmacologic intervention would automatically lead
to improved survival has not been validated. This revelation
became evident from trials of positive inotropic agents that did
not improve survival (25–29) and from trials with ACE inhib-
itors that improved survival without significant improvement in
myocardial left ventricular ejection fraction (3,6). The neuro-
hormonal activation that occurs with chronic CHF is thought
to be an important pathologic process in the deterioration of
myocardial function. One current need in the management of
patients with CHF is a more objective means of assessing
long-term response to treatment. Global indices of left ven-
tricular function (e.g., ejection fraction) have a limited prog-
nostic value in patients with uniformly impaired myocardial
function. Other tests would be a welcome addition to the
clinical arena if such markers were noninvasive, less expensive
and more accurate in their assessment. This study was designed
to test whether the cytokines TNF-alpha and IL-6, neurohor-
monal activation products, are reduced with use of amlodipine
and have predictive value for survival.
Previous studies have found that TNF-alpha is elevated in
patients with CHF compared with control subjects, and higher
levels were associated with greater severity of failure (12,19–
21,30,31). The elevation of the cytokines TNF-alpha and IL-6
observed in this study is consistent with these studies. Recently,
Torre-Amione et al. (32) investigated whether TNF-alpha and
IL-6 levels correlated with survival in patients with impaired
left ventricular systolic function in the Studies of Left Ventric-
ular Dysfunction trial. In that study, a trend toward signifi-
cance was noted with TNF-alpha levels and survival (p , 0.07),
whereas no significant relation was noted for IL-6 levels (p ,
0.072). However, previous studies have not assessed prospec-
tively whether treatment with a vasodilator like amlodipine
significantly affected TNF-alpha or IL-6 levels.
Similar to the previous study by Torre-Amione et al. (32), a
statistically significant reduction in TNF-alpha levels for
treated patients was not observed in this study. However,
patients treated with amlodipine had lower levels of IL-6 than
those treated with placebo after 26 weeks of therapy, indicating
that the beneficial effect of amlodipine may be due to a
reduction in IL-6 levels. Using the combined end point of CHF
and death or using death alone as the end point, IL-6 levels
were higher in those patients with an event. An increase in the
OR was detected for both IL-6 and functional class; statistical
significance was not achieved, probably because of a lack of
power. However, the combination of IL-6 and functional class
was a statistically significant predictor of survival. A larger
patient sample size should allow a definitive conclusion as to
whether IL-6 is a predictor of survival.
Despite the known pathophysiologic actions of TNF-alpha
in experimental models, its clinical importance in CHF is still
debated (13). The data supporting a role for TNF-alpha in
CHF is weakened because various assays (either immunologic
or biologic) have different sensitivities in TNF-alpha measure-
ment (33,34). The sensitivity and specificity of immunologic
assays also have been questioned because circulating TNF-
alpha was not detected in some patients, despite the presence
of severe CHF. The assay used in our study is highly sensitive
for detecting TNF-alpha in plasma, and thus is not likely to be
limited by a high sensitivity threshold.
Another possible explanation for the discrepancy in labo-
ratory results may be explained by the interaction of TNF-
alpha with its receptors. Two TNF-alpha receptors (tumor
necrosis factor receptors 1 and 2) have been identified on the
surface of several cell lines, including human myocardium (35).
The biologic effects of TNF-alpha are thought to be mediated
through binding and activation of these two receptors (35).
Both receptors’ extracellular domain fragments shed from the
cell surfaces can be detected as soluble forms in the urine and
blood. The levels of immunoreactive TNF-alpha measured by
ELISA in this study are not masked by either receptor protein,
which makes false negative results unlikely (34). As outlined by
Packer (13) in a recent editorial, these soluble proteins may
either neutralize the biologic action of TNF-alpha (34,36) or
enhance the biologic action by prolonging the half-life of
TNF-alpha (37), or do neither, but provide a sensitive marker
for the interaction of the cytokine and its target cells (13).
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Thus, the biologic activity of TNF-alpha is still being investi-
gated, and measurement of soluble TNF-alpha receptors
seems warranted to fully understand the role of this cytokine in
CHF. Furthermore, because cytokines are produced locally
within the heart (38,39), peripheral levels may not necessarily
be reflective of the changes in cytokine levels within the heart.
Interleukin-6 exerts its activity through binding to a high
affinity receptor complex consisting of two membrane glyco-
proteins—an 80-kDa IL-6–binding receptor protein (IL-6R)
and a 130-kDa signal-transducing protein (gp130) (40–42).
The affinity for IL-6 with IL-6R alone is low and IL-6 does not
bind to gp130. However, the presence of IL-6R together with
gp130 will result in formation of high affinity IL-6 binding and
subsequent signal transduction (43). A naturally occurring
soluble form of IL-6R, which binds IL-6, has been identified in
the serum and urine of humans (44–47). Currently, regulation
of the in vivo production of soluble IL-6R, as well as its
physiologic significance, is not well understood. Nevertheless,
elevated soluble IL-6R levels have been associated with a
number of pathologic states, including multiple myelomas,
adult T cell leukemia and human immunodeficiency virus
infection (48). Further study of the effects of pharmaceutical
agents on IL-6 levels in patients with CHF seems warranted
given the results of this study.
Conclusions. We found TNF-alpha and IL-6 levels to be
elevated in patients with chronic severe CHF. Patients treated
with amlodipine had significantly lower levels of IL-6 at 26
weeks after initiation of treatment compared with those receiv-
ing placebo. An adverse event—CHF or death—was more
likely to occur in patients with higher IL-6 levels. The benefi-
cial effects of amlodipine in patients with CHF may be due to
a reduction of cytokines such as IL-6.
We thank Naomi Fineberg, PhD, for her assistance with statistical analysis.
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